Drug Profile
Research programme: Ebola virus vaccines - AmVac
Alternative Names: AMV-701Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator AmVac
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Ebola-virus-infections(Prevention) in Switzerland (Parenteral)
- 31 Dec 2014 Early research in Ebola virus infections (Prevention) in Switzerland in the fourth quarter of 2014 (Parenteral)